Aastrom Stands Behind Its Decision To Shift Gears In Late Stages
This article was originally published in The Pink Sheet Daily
Executive Summary
The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.
You may also be interested in...
Aastrom Adds Revenues Through $6.5M Regen Med Buy From Sanofi
The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.
Venture Investing In Biotech Still Strong, Says E&Y Report
The 27th annual Beyond Borders report shows continued constraints to funding for biotechs, as they cut R&D and deal with a changing development landscape, but VC funding remains resilient.
Newly Appointed Head of Regenerative Medicine At Shire Plans Rapid Growth For The Division
Jeff Jonas takes over Shire’s newly formed Regenerative Medicine business with plans for rapid growth, replacing Advanced BioHealing’s Kevin Rakin in the role.